The increase in price target by Scotiabank reflects a positive outlook on Biomarin Pharmaceutical's stock, likely due to anticipated performance or favorable market conditions. This adjustment suggests confidence in the company's future prospects, potentially leading to increased investor interest and a positive short-term impact on the stock price.